Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Study of Bomedemstat in Combination with Atezolizumab in Small Cell Lung Cancer

Imago BioSciences, Inc. announced that the first participant has been treated in an investigator-sponsored Phase I/II study of bomedemstat in combination with atezolizumab during the maintenance phase of treatment in people newly diagnosed with extensive stage small cell lung cancer.